基于索磷布韦的四联方案对4型丙型肝炎病毒感染且直接抗病毒药物治疗失败的埃及患者非常有效。 - Suppr

Suppr

超能文献

A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.

作者信息

Abdel-Moneim Adel, Aboud Alaa, Abdel-Gabbar Mohamed, Zanaty Mohamed I, Ramadan Mohamed

机构信息

Molecular Physiology Division, Faculty of Science, Beni-Suef University, Egypt.

Tropical Medicine Department, Faculty of Medicine, Beni-Suef University, Egypt.

出版信息

J Hepatol. 2018 Jun;68(6):1313-1315. doi: 10.1016/j.jhep.2018.03.010. Epub 2018 Apr 3.

DOI:10.1016/j.jhep.2018.03.010

PMID:29625827

Abstract

摘要

相似文献

A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.基于索磷布韦的四联方案对4型丙型肝炎病毒感染且直接抗病毒药物治疗失败的埃及患者非常有效。

J Hepatol. 2018 Jun;68(6):1313-1315. doi: 10.1016/j.jhep.2018.03.010. Epub 2018 Apr 3.

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.西米普明、达卡他韦、索磷布韦治疗丙型肝炎病毒1型感染6周或8周的疗效与安全性

J Viral Hepat. 2018 Jun;25(6):631-639. doi: 10.1111/jvh.12853. Epub 2018 Feb 6.

Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection.西米普明或达卡他韦联合索非布韦治疗丙型肝炎基因4型感染的疗效和安全性

J Clin Gastroenterol. 2018 May/Jun;52(5):452-457. doi: 10.1097/MCG.0000000000000896.

Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.索磷布韦-达拉他韦-西美瑞韦联合利巴韦林治疗慢性丙型肝炎直接作用抗病毒药物治疗经验患者。

Clin Infect Dis. 2017 Jun 1;64(11):1615-1618. doi: 10.1093/cid/cix214.

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.达卡他韦联合索非布韦治疗 HCV 基因 1 型单感染患者的安全性和疗效。

J Hepatol. 2017 Jan;66(1):39-47. doi: 10.1016/j.jhep.2016.08.021. Epub 2016 Sep 10.

Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.索磷布韦联合达拉他韦治疗伴有或不伴有利巴韦林的慢性丙型肝炎病毒基因型 4 患者的疗效和安全性：真实世界大样本研究结果。

Hepatol Int. 2018 Jul;12(4):348-355. doi: 10.1007/s12072-018-9868-8. Epub 2018 May 12.

Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).西米普明联合索磷布韦用于初治和经治的丙型肝炎病毒4型感染患者：一项III期开放标签单臂研究（冥王星研究）

Aliment Pharmacol Ther. 2017 Feb;45(3):468-475. doi: 10.1111/apt.13883. Epub 2016 Nov 29.

On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.治疗中 HCV RNA 作为聚乙二醇干扰素联合利巴韦林治疗失败的慢性丙型肝炎患者应用达卡他韦和索非布韦治疗的预测因素。

Liver Int. 2016 Nov;36(11):1611-1618. doi: 10.1111/liv.13165. Epub 2016 Jun 16.

Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.索磷布韦联合利巴韦林治疗肝硬化合并基因 2 型 HCV 感染患者：真实世界经验。

J Hepatol. 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. Epub 2016 Dec 10.

Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.对于初治和经治的丙型肝炎病毒4型患者，无论有无肝硬化，使用西米普明加索非布韦治疗8周或12周。

J Viral Hepat. 2017 Feb;24(2):102-110. doi: 10.1111/jvh.12625. Epub 2016 Oct 27.

引用本文的文献

The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting.资源有限环境下复发性丙型肝炎病毒感染再治疗的结果

Virusdisease. 2021 Sep;32(3):582-588. doi: 10.1007/s13337-021-00712-4. Epub 2021 Jul 27.

Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment.对接受直接抗病毒药物治疗失败的埃及患者中丙型肝炎病毒G4a耐药相关替代位点的深度测序研究。

Infect Drug Resist. 2019 Sep 10;12:2799-2807. doi: 10.2147/IDR.S214735. eCollection 2019.

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4.索磷布韦联合利巴韦林或simeprevir：丙型肝炎基因4型患者的真实研究

Ann Gastroenterol. 2019 Jan-Feb;32(1):93-98. doi: 10.20524/aog.2018.0327. Epub 2018 Nov 24.

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?索磷布韦、维帕他韦和伏西瑞韦：丙型肝炎病毒治疗的新型三联组合。一药通用？这是终点吗？

Therap Adv Gastroenterol. 2018 Dec 2;11:1756284818812358. doi: 10.1177/1756284818812358. eCollection 2018.

Treatment of hepatitis C virus genotype 4 in the DAA era.DAA 时代丙型肝炎病毒基因型 4 的治疗。

Virol J. 2018 Nov 22;15(1):180. doi: 10.1186/s12985-018-1094-4.

Hepatol Int. 2018 Jul;12(4):348-355. doi: 10.1007/s12072-018-9868-8. Epub 2018 May 12.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验